San Diego, CA, USA, and Munich, Germany – October 21, 2025 – selectION, Inc. (“selectION” or the “Company”), a clinical-stage biopharmaceutical company developing novel treatments for T cell-mediated autoimmune diseases, today announced the successful completion of its phase 1b proof-of-concept trial evaluating si-544, a first-in-class Kv1.3 blocker in patients diagnosed with psoriasis vulgaris.
-
Best-in-class Kv1.3 blocker
-
Benchmark for safety and tolerability in autoimmune therapy
-
Maintains patient’s full immunocompetence
-
Short treatment course delivers sustained clinical benefit
-
Pipeline drug for autoimmunity
Our Goal
To improve quality of life for patients by developing best-in-class ion channel blockers.
Our Technology
A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.
News & Events
Congratulations to our Scientific Advisor, Dr. Fred Ramsdell, for receiving the 2025 Nobel Prize in Physiology.
His groundbreaking work on T cells and immune regulation has paved the way for innovative immunotherapies, offering new hope to millions of patients living with autoimmune and inflammatory diseases. Dr. Ramsdell’s visionary science continues to inspire us all at selectION as we work toward advancing immune-based treatments that change lives.
Read More